An important review in a mainstream periodical read by cardiologist colleagues.
ALERT!
This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
Heart Failure - Ischemic
February 7, 2019
In the February issue of The Annals, The Society of Thoracic Surgeons published the first annual report after the Interagency Registry for Mechanically Assisted Circulatory Support (Intermacs) joined the STS National Database in January 2018. This report summarizes the outcomes in patients (≥19 years of age) undergoing durable MCS implant b
February 5, 2019
In a letter to healthcare providers, the US FDA summarized a recent evaluation of a postapproval study of the Abiomed Impella RP system. In clinical trials, 73% of patients survived 30 days after device explant, hospital discharge, or to definitive intervention. In the postapproval study, just over 17% of patients met this goal.
January 30, 2019
Garbade and colleagues compared outcomes reported during the European Conformity (CE) Mark clinical trial of the HeartMate 3 left ventricular assist device (LVAD) to outcomes for patients treated since the device came to market.
December 26, 2018
A randomized controlled trial coauthored by the Editor-in-Chief of the host periodical on the risk management of multivessel diabetic coronopathy.
October 23, 2018
A post-market study (ELEVATE registry) of the fully magnetically levitated continuous flow HeartMate III left ventricular assist device (LVAD) found no pump thrombosis in 463 patients in Europe and Kazakhstan.
July 6, 2018
A detailed and somewhat disheartening analysis of stem cell therapy for cardiac failure.
March 27, 2018
A brief readable editorial on a retrospective analysis of the costs of coronary artery bypass grafting in Virginia, USA, which suggests the value of enhanced recovery in coronopathy.
March 16, 2018
Patient Care
Some Syrian refugee children have received surgery for congenital heart defects in Jordan, however many refugees in need of complex medical care are unable to receive such care.
March 12, 2018
An interesting two-year report from the MOMENTUM 3 randomized controlled trial comparison of HeartMate 3 and II, the analysis performed by Abbott. Although stroke and reoperation were clearly lower with the latest technology, reflected in the lower LDH measurements, there was bafflingly no improvement in survival.